Designing safer medicines in discovery: current and emerging opportunitiesActivity by Jacqui Colgate | added on Nov 18, 2010 | United Kingdom
This meeting will look at how better Clinical Candidates can be designed with an enhanced awareness of potential future safety issues.
Designing safer medicines in discovery: current and emerging opportunitiesSCI HQ, London, UK
17 March 2011, 09.30 - 18.30
Organised by SCI's Fine Chemicals Group
This meeting will look at how better Clinical Candidates can be designed
with an enhanced awareness of potential future safety issues.
The current success rate for delivering a marketed drug from a nominated candidate drug is approximately 5% and much lower from the start of chemical optimization. It has been estimated that a 5-10% improvement in this attrition rate could double the output of marketed drugs with concomitant benefit to all.
Following the focus on pharmacokinetics and drug metabolism in the discovery process during the 1990’s, the causes of this have attrition shifted, with drug toxicity accounting for a significant proportion of drug failures. This has led to an increased focus on developing improved preclinical safety screening strategies and compound design principles and this meeting will provide practical insights into some of the recent improvements and future directions in this key area.
This meeting is targeted at all those who are involved in the lead identification and lead optimization processes in Drug Discovery and those interested in furthering their knowledge of current and emerging approaches to designing safer Drug CandidatesProgramme
Please click here to view the full programme.
Registration and refreshments
The Safety Related Attrition Challenge - A Medicinal Chemists Perspective
Steve Swallow, AstraZeneca
Increasing the Probability of Compound Survival: Aligning Metabolism, Permeability, and Safety Properties
Anabella Villalobos, Pfizer
Off Target Pharmacology Profiling: Impact on Discovery Projects
Joanne Bowes, AstraZeneca
Using Lessons from the Clinic to Inform Early Discovery: Molecular Clinical Safety Intelligence in GSK
James Bailey, GlaxoSmithKline
Medicinal Chemistry Strategies to Address Bioactivation Liabilities in Drug Discovery
Tom Baillie, University of Washington
Stem Cell derived Cardiomyocytes as a tool to Predict Safety
Kyle Kolaja, Roche
Reducing Attrition Risk: evaluation of an in silico “MedChem Risk Score”
Kevin Dack, Pfizer
To be announced (Novartis)
Medicinal Chemists: How can We Reduce Attrition?
Juliet Simpson, GlaxoSmithKline
Avoiding aromatic hydrocarbon receptor liability in drug candidates
Jim Damewood, AstraZeneca
Newer methods of predicting toxicity: characterising mechanisms of toxicity
Mark Gosink, Pfizer
Wine receptionOrganising Committee
Dr Stephen Smith, Stort MedChem Consulting
Dr Alan Stobie, Pfizer
Dr Steve Swallow, AstraZeneca
SCI HQ, London, UK
Please click here for a location map.
Please note fees include the 5% discount for making an online booking
Earlybird fees - before 17 February
GB£115.00 . . . . . . . . SCI Member
GB£30.00 . . . . . . . ... SCI Student
GB£60.00 . . . . . . . ... Subsidised Member
GB£150.00 . . . . . . ... Non Member
Standard fees - after 17 February
GB£140.00 . . . . . . ... SCI Member
GB£35.00 . . . . . . . . ..SCI Student
GB£70.00 . . . . . . . ... Subsidised Member
GB£180.00 . . . . . . ... Non Member
T: +44 (0)20 7598 1561
F: +44 (0)20 7235 7743